gem103
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 19, 2019 (NCT04246866)
Timeline
Indications
Mechanism of action
- Complement factor HINHIBITOR
CFH inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04684394 | Phase 2 | Dec 30, 2020 | Gemini Therapeutics, Inc. |
| NCT04643886 | Phase 2 | Jul 30, 2020 | Gemini Therapeutics, Inc. |
| NCT04246866 | Phase 1 | Dec 19, 2019 | Gemini Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gemini Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2019 |
1 organizations
Page 1 / 1